CSS
BIOL

Cubist Systematic Strategies’s Biolase, Inc. BIOL Stock Holding History

Cubist Systematic Strategies’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-358
Closed -$2.53K – 4103
2023
Q2 		$2.53K Buy
+358
New +$5.99K ﹤0.01% 3344

Other funds holding BIOL

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
ZF
Zhang Financial Portage, Michigan $2.89B AUM 18.44% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Cubist Systematic Strategies's BIOL Position: Q3 2023 in Review

Cubist Systematic Strategies sold out of Biolase, Inc. (BIOL) in Q3 2023, closing a stake of 358 shares — an estimated $2.53K sold.

Cubist Systematic Strategies first reported a position in BIOL in Q2 2023 and held it in 1 quarter. The position peaked at $2.53K in Q2 2023. 12 funds tracked by Wall St. Rank hold BIOL as of Q3 2023.

  • Cubist Systematic Strategies reported no remaining Biolase, Inc. position as of Q3 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 358 Biolase, Inc. shares in Q3 2023, an estimated $2.53K.
  • Cubist Systematic Strategies first reported a position in Biolase, Inc. in Q2 2023 and held it in 1 quarter.
  • Cubist Systematic Strategies's Biolase, Inc. position peaked at $2.53K in Q2 2023.
  • 12 funds tracked by Wall St. Rank held Biolase, Inc. as of Q3 2023.

Based on Cubist Systematic Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.